(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
5 July 2012 (05.07.2012)

WIPO | PCT

(10) International Publication Number
WO 2012/091153 A3

(51) International Patent Classification:
A61K 9/20 (2006.01) *A61K 31/4439* (2006.01)
A61K 9/50 (2006.01) *A61K 9/00* (2006.01)

(21) International Application Number:
PCT/JP2011/080568

(22) International Filing Date:
26 December 2011 (26.12.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/427,384 27 December 2010 (27.12.2010) US

(71) Applicant *(for all designated States except US)*: **TAKEDA PHARMACEUTICAL COMPANY LIMITED** [JP/JP]; 1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka, 5410045 (JP).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **ISHII, Shiro** [JP/JP]; c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka-shi, Osaka, 5320024 (JP). **EBISAWA, Yutaka** [JP/JP]; c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka-shi, Osaka, 5320024 (JP). **OKABE, Takayuki** [JP/JP]; c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka-shi, Osaka, 5320024 (JP).

(74) Agent: **TAKASHIMA, Hajime**; Meiji Yasuda Seimei Osaka Midosuji Bldg., 1-1, Fushimimachi 4-chome, Chuo-ku, Osaka-shi, Osaka 5410044 (JP).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:
7 September 2012

(54) Title: ORALLY DISINTEGRATING TABLET

(57) Abstract: Provided is an orally disintegrating tablet obtained by tableting fine granules showing controlled release of lansoprazole and an additive, which is capable of suppressing breakage of the fine granules during tableting, and can control the release of lansoprazole for a long time, and can maintain a therapeutically effective concentration for a prolonged time, and shows superior disintegration property in the oral cavity. An orally disintegrating tablet containing (i) fine granules showing controlled release of a pharmaceutically active ingredient, which contains fine granules containing a pharmaceutically active ingredient and a coating layer containing a methacrylic acid/methyl acrylate/methyl methacrylate copolymer, wherein the fine granules containing a pharmaceutically active ingredient are coated with more than 80 wt% and not more than 300 wt% of the copolymer, and (ii) fine granules showing controlled release of a pharmaceutically active ingredient, which contains the pharmaceutically active ingredient and a coating layer comprising (a) an ethyl acrylate/methyl methacrylate copolymer, and (b) one or more kinds of polymers selected from the group consisting of methacrylic acid/ethyl acrylate copolymer, hypromellose phthalate, carboxymethylethylcellulose, polyvinyl acetate phthalate, hydroxypropyl methylcellulose acetate succinate and cellulose acetate phthalate, wherein the fine granules (i) and fine granules (ii) have an average particle size of not more than 500 micrometer, and the pharmaceutically active ingredient is lansoprazole or an optically active form thereof or a salt thereof.

WO 2012/091153 A3